Results were in line with reaffirmed guidance, with core operating income flat in Q2. The key swing factors to watch are Entresto's continued generic erosion trajectory and the outcome of the Lutathera patent appeal. Pipeline catalysts in H2 include Kisqali overall survival data and regulatory decisions for Cosentyx in PMR and ianalumab in Sjögren's. The elevated debt load from M&A may limit near-term buyback acceleration.
Price Chart
Executive Summary
Novartis reported Q2 2026 net sales of $14.4B (+3% USD, +1% cc), with core operating income flat at $5.9B (0% cc). Net income declined -19% to $3.3B due to higher taxes and interest expense. Full-year guidance was reaffirmed: low single-digit net sales growth and low single-digit core operating income decline. Strong growth from Kisqali (+43% cc), Kesimpta (+32% cc), and Scemblix (+89% cc) was offset by generic erosion of Entresto (-51% cc). Net debt rose to $39.4B following the $12B Avidity acquisition.
Key Facts
- Q2 net sales $14.4B (+3% USD, +1% cc); H1 net sales $27.5B (+1% USD, -2% cc)
- Q2 core operating income $5.9B (flat cc); core EPS $2.41 (0% USD, -1% cc)
- Q2 net income $3.3B (-19% cc); EPS $1.71 (-18% cc)
- Q2 free cash flow $5.6B (-12%)
- Full-year 2026 guidance reaffirmed: net sales low single-digit growth, core operating income low single-digit decline (cc)
- Kisqali +43% cc, Kesimpta +32% cc, Scemblix +89% cc, Pluvicto +43% cc, Leqvio +59% cc
- Entresto -51% cc due to US generic competition; Promacta -65% cc, Tasigna -58% cc
- Lutathera patent invalidity ruling in Delaware; appeal filed
- Avidity acquisition closed Feb 2026 for ~$12B; Pikavation ($1.8B) and Excellergy ($0.9B) closed in Q2
- Net debt increased to $39.4B from $21.9B at Dec 2025; debt/equity ratio 1.12:1
- Share buyback: $2.8B in H1 2026; $5.6B remaining under $10B program
Financial Impact
Q2 net sales +3% USD, operating income -2%, net income -19%. Core operating income flat. H1 net sales +1%, operating income -6%, net income -16%. Net debt increased $17.5B to $39.4B.
Risk Factors
- Lutathera patent invalidity ruling could open door to generic competition if appeal fails
- Entresto sales declining ~50% YoY due to US generics, a major headwind to total revenue
- Net debt of $39.4B and debt/equity ratio of 1.12:1 increase financial leverage
- Higher interest expense ($462M in Q2 vs $289M) pressuring net income
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001114448-26-000012 |
| Document: nvs-20260630-99_1.htm | 0001114448-26-000012 |
| Document: nvs-20260630.htm | 0001114448-26-000012 |
| Document: 0001114448-26-000012-index-headers.html | 0001114448-26-000012 |
| Document: 0001114448-26-000012-index.html | 0001114448-26-000012 |
| Document: 0001114448-26-000012.txt | 0001114448-26-000012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 6-K | $137.70 $138.62 | ▼ −0.67% | ▼ −1.79% | $141.00 (−2.40%) |
Sep 1, 2026 4w ago | 6-K | $161.25 $137.48 | ▼ −14.74% | ▼ −14.82% | $141.00 (−12.56%) |
Aug 4, 2026 8w ago | Court Ruling | $153.27 $154.61 | ▲ +0.87% | ▲ +0.97% | $141.00 (−8.01%) |
Jul 28, 2026 9w ago | Court Ruling | $159.85 $153.67 | ▼ −3.87% | ▼ −6.14% | $141.00 (−11.79%) |
Jul 21, 2026 10w ago | 6-K | $153.87 $156.11 | ▲ +1.46% | ▲ +2.68% | $141.00 (−8.36%) |
Jul 1, 2026 13w ago | Court Ruling | $154.14 $157.03 | ▼ −1.87% | ▼ −1.61% | $141.00 (+8.52%) |
Apr 30, 2026 22w ago | Court Ruling | $147.85 $148.36 | ▼ −0.34% | ▲ +1.38% | $141.00 (+4.63%) |
Apr 14, 2026 24w ago | Court Ruling | $153.38 $147.97 | ▲ +3.53% | ▲ +4.92% | $141.00 (+8.07%) |
Mar 30, 2026 26w ago | Court Ruling | $150.36 $151.22 | ▲ +0.57% | ▼ −3.73% | $141.00 (−6.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access